Pedro Perez: Are We Measuring the Right Outcomes in VTE?
Pedro Perez, Senior Vascular Consultant at Argon Medical Devices, Inc., shared a post on LinkedIn:
”Are We Measuring the Right Outcomes in VTE?
In VTE, we often talk about technical success:
- Did we remove the clot?
- Did flow improve?
- Did the case go smoothly?
But the bigger question is… does that actually define success for the patient?
Because what matters long-term isn’t just what happens in the lab – it’s what happens after:
- Reduction in post-thrombotic syndrome
- Improvement in quality of life
- Decreased readmissions
- Shorter hospital stays and overall cost of care
As technology continues to evolve – from aspiration to more advanced thrombectomy approaches – we’re getting better at treating clot.
But as an industry, we need to continue shifting the conversation from procedural metrics to patient outcomes.
The next phase of VTE care won’t be defined by who has the newest device…
It will be defined by who can demonstrate meaningful, measurable impact on patients.”
Stay updated with Hemostasis Today.
-
Apr 24, 2026, 17:58Erwin Loh: Triple Combination Therapy Shows Major Benefit in Preventing Recurrent Stroke
-
Apr 24, 2026, 17:51Mostafa Faisal Mohammed Saleh: Exploring the Impact of PNH Clones in Aplastic Anemia Across Different Treatment Strategies
-
Apr 24, 2026, 17:35Dawn Faller: Strengthening Global Collaboration in Apheresis at the 2026 ASFA and WAA Joint Meeting
-
Apr 24, 2026, 17:30Omar Adwan: Easy-to-Remember Tips for MCV
-
Apr 24, 2026, 17:07Melissa Hollo: Revolutionizing Diagnostics Through Real-Time Anemia Management at Executive War College
-
Apr 24, 2026, 17:03Oscar William-Donkor: Faith, Blood and Choice
-
Apr 24, 2026, 17:01Julie Rayes: Presenting Our Data at the 12th Symposium on Hemostasis
-
Apr 24, 2026, 16:56Nazish Saqlain: Hands-on Training Workshop in Transfusion Medicine and Immunohematology
-
Apr 24, 2026, 16:49Michael Greger: Most Heart Attacks Are Triggered by Non-Obstructive Plaques